JBC Transcription and Nuclear Factor Monoclonals

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M507016200 on July 15, 2005

J. Biol. Chem., Vol. 280, Issue 38, 32957-32967, September 23, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/38/32957    most recent
M507016200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rockenstein, E.
Right arrow Articles by Masliah, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rockenstein, E.
Right arrow Articles by Masliah, E.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

High {beta}-Secretase Activity Elicits Neurodegeneration in Transgenic Mice Despite Reductions in Amyloid-{beta} Levels

IMPLICATIONS FOR THE TREATMENT OF ALZHEIMER DISEASE*

Edward Rockenstein{ddagger}, Michael Mante{ddagger}, Michael Alford{ddagger}, Anthony Adame{ddagger}, Leslie Crews{ddagger}, Makoto Hashimoto{ddagger}, Luke Esposito§, Lennart Mucke§, and Eliezer Masliah{ddagger}||1

From the {ddagger}Neurosciences and ||Pathology, University of California, San Diego, School of Medicine, La Jolla, California 92093-0624 and the §Gladstone Institute of Neurological Disease and Department of Neurology, University of California, San Francisco, California 94158

Received for publication, June 28, 2005 , and in revised form, July 13, 2005.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Amyloid-{beta} peptides (A{beta}) are widely presumed to play a causal role in Alzheimer disease. Release of A{beta} from the amyloid precursor protein (APP) requires proteolysis by the {beta}-site APP-cleaving enzyme (BACE1). Although increased BACE1 activity in Alzheimer disease brains and human (h) BACE1 transgenic (tg) mice results in altered APP cleavage, the contribution of these molecular alterations to neurodegeneration is unclear. We therefore used the murine Thy1 promoter to express high levels of hBACE1, with or without hAPP, in neurons of tg mice. Compared with hAPP mice, hBACE1/hAPP doubly tg mice had increased levels of APP C-terminal fragments (C89, C83) and decreased levels of full-length APP and A{beta}. In contrast to non-tg controls and hAPP mice, hBACE1 mice and hBACE1/hAPP mice showed degeneration of neurons in the neocortex and hippocampus and degradation of myelin. Neurological deficits were also more severe in hBACE1 and hBACE1/hAPP mice than in hAPP mice. These results demonstrate that high levels of BACE1 activity are sufficient to elicit neurodegeneration and neurological decline in vivo. This pathogenic pathway involves the accumulation of APP C-terminal fragments but does not depend on increased production of human A{beta}. Thus, inhibiting BACE1 may block not only A{beta}-dependent but also A{beta}-independent pathogenic mechanisms.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The precise mechanisms leading to neurodegeneration in Alzheimer disease (AD)2 are not completely understood. However, diverse lines of evidence suggest that alterations in the processing of the amyloid precursor protein (APP), leading to the accumulation of amyloid-{beta} peptides (A{beta}), play a key role in the pathogenesis of AD (1–3). Various products are derived from APP through alternative proteolytic cleavage, and enormous progress has recently been made in identifying the enzymes involved (3–11).

Cleavage of APP by {alpha}-secretase results in the secretion of a large N-terminal ectodomain. In an alternative pathway, {beta}-secretase generates a shorter secreted N-terminal fragment and APP C-terminal fragments (CTFs) C89 and C99, which remain membrane-bound. The latter fragments are then further cleaved by {gamma}-secretase, resulting in the production of A{beta} peptides. The {beta}-site APP-cleaving enzyme (BACE1) accounts for most of the {beta}-secretase activity in the brain (1, 5–7, 9). BACE1 is a typical aspartic protease; cleavage of the prodomain to generate the mature enzyme occurs at the C-terminal site resulting in the generation of a mature protein starting at Glu-46 (12).

Recent evidence suggests that the pathogenesis of AD involves alterations in the activity of BACE1. A polymorphism in the BACE1 gene has been reported to influence AD risk (13). Compared with nondemented controls, BACE1 immunoreactivity was increased around amyloid plaques in AD brains; levels of BACE1 were elevated in AD brain homogenates (14–17) and correlated with the levels of APP CTFs and with A{beta}1–x and A{beta}1–42 (18). The potential pathogenic role of increased BACE activity has been investigated in vivo by analyzing the metabolism of APP in human (h) BACE transgenic (tg) mice (19–22). These studies have shown that expression of hBACE1 at moderate levels in hAPP tg models results in increased generation of hAPP CTFs and A{beta}, which in some cases was associated with enhanced amyloid deposition. These studies have confirmed the importance of hBACE1 in APP processing in vivo. However, the relationship between high levels of hBACE1 activity, APP processing, and neurodegeneration remains to be established. To address this issue, we used the strong Thy1 promoter to express hBACE1 in neurons of tg mice, either alone or in combination with hAPP. High levels of BACE1 activity significantly increased the cerebral accumulation of hAPP CTFs, but not of A{beta}, and caused prominent age-related neurodegeneration and neurological decline.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Generation of hBACE1 and hBACE1/hAPP tg Mice and Tissue Processing—A cDNA encoding wild-type hBACE1 was produced by reverse transcription-PCR from human brain mRNA as described previously (23). This cDNA includes a Kozak consensus sequence (GCC ACC ATG) at the 5'-end to enhance expression. The hBACE1 cDNA was inserted between exons 2 and 4 into the mThy1 expression cassette (kindly provided by Dr. H. van der Putten, Ciba-Geigy, Basel, Switzerland), purified, and microinjected into one-cell embryos (C57BL/6 x DBA/2 F1). Transgenic founder mice were identified by PCR analysis of genomic DNA extracted from tail biopsies. Doubly tg mice were generated by crossing heterozygous hBACE1 mice from lines 1 or 39 with the hAPP tg line 41 we described previously (23). hAPP line 41 expresses mutant hAPP751 under the direction of the mThy1 promoter and produces high levels of A{beta}1–42 resulting in plaque formation by 3 months of age. All tg lines were maintained by crossing heterozygous tg mice with non-tg C57BL/6 x DBA/2 F1 breeders. All tg mice analyzed in this study were heterozygous with respect to individual transgenes, and non-tg littermates were used as controls.

At different ages, mice were anesthetized with chloral hydrate and flush-perfused transcardially with 0.9% saline. Brains and peripheral tissues were removed and brains divided sagittally. One hemibrain was postfixed in phosphate-buffered 4% paraformaldehyde, pH 7.4, at 4 °C for 48 h for neuropathological analysis. The other was snap frozen and stored at -70 °C for RNA and protein analyses.

RNA Analysis—Total RNA was extracted with TRI reagent (Molecular Research Center, Cincinnati, OH) from snap frozen hemibrains or dissected brain regions (neocortex and hippocampus) and stored in formazol buffer (Molecular Research) at -20 °C. RNA was analyzed by solution hybridization ribonuclease protection assay (RPA), essentially as described previously (24). Samples were separated on 5% acrylamide, 8 M urea Tris borate, EDTA gels, and dried gels were exposed to Kodak XAR film (Eastman Kodak). mRNA levels were quantitated from PhosphorImager readings of probe-specific signals corrected for RNA content/loading errors by normalization to {beta}-actin signals (24). The following 32P-labeled antisense riboprobes were used to identify specific mRNAs (protected nucleotides and GenBank accession numbers): hBACE1 (nucleotides 1305–1599, accession number AF190725 [GenBank] ); mouse (m) BACE1 (1280–1574, accession number AF190726 [GenBank] )); mAPP770 (811–1314, accession number XM_128362 of mAPP exon 6–9; and m{beta}-actin (480–565, accession number X03672 [GenBank] ).

Western Blot Analysis of hBACE1, hAPP, APP CTFs, and A{beta}—After determination of the protein content by the Lowry method, frontal cortex homogenates were loaded (15 µg of protein/lane), separated on 10% SDS-polyacrylamide gels, and blotted onto nitrocellulose. Blots were labeled with a rabbit polyclonal antibody against hBACE1 (ProSci, Inc., Poway, CA; 1:1,000), a mouse monoclonal antibody against the N terminus of APP (22C11; Chemicon International, Temecula, CA; 1:1,000), a mouse monoclonal antibody against hAPP (8E5; Elan; 1:20,000), a rabbit polyclonal antibody against C99 and C89 of APP (CT15; courtesy of Dr. Edward Koo; 1:20,000), or a mouse monoclonal antibody against A{beta} (4G8; Senetek PLC, Napa, CA; 1:1,000) followed by anti-mouse or anti-rabbit secondary antibodies. The blots were incubated with 125I-protein A (ICN Pharmaceuticals, Costa Mesa, CA) and exposed to PhosphorImager (Molecular Dynamics, Piscataway, NJ) screens, or incubated with Super Signal West Pico Chemiluminescent substrate (Pierce) and exposed to film. Further details regarding the antibodies utilized are described in TABLE ONE. To control for variations in loading, blots were stripped and incubated with a mouse monoclonal antibody against actin (Chemicon; 1:500). Signal intensities were quantitated with the ImageQuant software (Molecular Dynamics).


View this table:
[in this window]
[in a new window]
  		TABLE ONE
Antibodies against BACE, APP, and APP metabolites used in this study

 
Additional Western blot analysis of A{beta} was performed under highly denaturing conditions as described previously (25), with some modifications. For this, neocortical tissues were homogenized in 98% formic acid (80% final concentration, ICN) with a Dounce homogenizer and centrifuged for 30 min at 50,000 x g at 4 °C. The supernatants were collected and used for highly denaturing acetic acid/urea-PAGE and Western blot analysis. Briefly, 1.0 mg (for mice without plaques) or 50 µg (for mice with plaques) of total protein (determined by the micro-Lowry assay) was loaded per lane on a 4/10/22% step gradient polyacrylamide gel containing 6 M urea and 10% acetic acid, and electrophoresed anode (+) to cathode (–) in 6.25% acetic acid running buffer overnight at 4 °C. The gel was then neutralized by five 15-min incubations in Tris/glycine transfer buffer (20% methanol), pH 8.4, and transferred to a nitrocellulose membrane (0.2 µm pore size). The membrane was boiled in phosphate-buffered saline for 5 min, blocked with 5% milk in Tris-buffered saline and 0.05% Tween 20 (TBS/T) for 1 h, and incubated overnight at 4 °C with the anti-A{beta} antibody 266 (5.7 µg/ml) (25). Membranes were then washed three times for 8 min in 1% bovine serum albumin in TBS/T and incubated in anti-mouse IgG/horseradish peroxidase secondary antibody for 3 h at room temperature. Membranes were washed three times for 8 min in TBS/T, and detection was carried out with Super Signal West Pico Chemiluminescent substrate (Pierce). Synthetic A{beta}1–40 and A{beta}1–42 peptides (750 pg each; Biopeptide, San Diego, CA) were run as standards.



View larger version (58K):
[in this window]
[in a new window]
  		FIGURE 1.
BACE1 expression in brains of BACE1 tg mice and non-tg controls. Brain tissues were obtained from 3-month-old tg mice of lines 1, 2, and 39, from age-matched non-tg controls, and a 60-year-old nondemented human. A–C, human (h) and mouse (m) BACE1 mRNAs in the frontal cortex were quantitated by RPA. A, representative autoradiograph. Each lane contains a sample from a different mouse or human. B, and C, relative mRNA levels were expressed as hBACE1/actin (B) and mBACE1/actin (C) ratios to correct for loading errors. RPA signals were quantitated as described previously (24). D, relative levels of hBACE1 protein in the frontal cortex were determined by Western blot analysis. A representative Western blot demonstrates the association of BACE1 with the particulate fraction. Each lane contains a sample from a different mouse. E, Western blot bands were quantitated with ImageQuant software. F, BACE1 activity was determined with a red FRET peptide substrate based on the SwAPP-mutant. This assay does not differentiate between the activities of human and murine BACE1. Levels in non-tg controls were defined as 100%. G–J, photomicrographs depicting immunoperoxidase staining for hBACE1 in the frontal cortex of a non-tg mouse (G) and hBACE1 tg mice from lines 39 (H),2(I), and 1 (J). Bar = 25 µm. *, p < 0.05 versus lines 39 and 2 (Tukey-Kramer test); **, p < 0.05 versus non-tg controls (Dunnett's t test).

 
Analysis of APP Metabolism and Related Pathways—Human A{beta} peptides were quantitated by enzyme-linked immunosorbent assays (ELISAs) as described previously (26). The A{beta}1–42 ELISA detects only A{beta}1–42, whereas the A{beta}1–x ELISA detects both A{beta}1–40 and A{beta}1–42, as well as other forms of A{beta} containing amino acids 1–28. For analysis of APP CTFs, cortex homogenates were analyzed with the Lowry method to determine protein concentration, loaded at 75 µg of protein/lane (or 25 and 50 µg/lane for J20 and I5 mice, respectively) onto 14% Tricine/SDS-polyacrylamide gels, blotted onto nitrocellulose, and probed with antibodies against APP CTFs (CT15; 1:1,000), phospho (p) APP (Cell Signaling, Beverly, MA; 1:1,200), or tubulin (loading control; 1:500,000).

To evaluate the effects of hBACE1 expression on related pathways, Western blots were probed with antibodies against neprilysin (CD10, mouse monoclonal; Abcam, Cambridge, MA; 1:1000), insulin-degrading enzyme (IDE, rabbit polyclonal; Calbiochem, San Diego, CA; 1:1,000), or Notch4 (rabbit polyclonal; Santa Cruz Biotechnology, Santa Cruz, CA; 1:1,000).

Analysis of BACE1 Enzymatic Activity—BACE1 activity was determined by adapting the BACE1 fluorescence resonance energy transfer (FRET) assay kit (Panvera, Madison, WI), which uses a red FRET peptide derived from the Swedish (Sw) mutant APP as the substrate sequence as described previously (6). Briefly, brain homogenates from the tg mice were incubated with the BACE1 substrate, for a final concentration of 1 x for each of the reagents. Then stop buffer (containing a 2.5 M sodium acetate) was added, and the signal was determined at 545 nm with a spectrofluorometer. Control experiments were performed, and standard curves were generated using the baculovirus-expressed BACE1 and the BACE1 product standard (Rh-EVNL, a BACE1 inhibitor) provided with the kit.

To confirm BACE1 activity levels by an independent method, extracted supernatants from homogenized samples were neutralized with Tris and assayed for BACE1 activity utilizing as a substrate the bacterial maltose-binding protein (MBP) fused to the C-terminal 125 amino acids of APP (MBP-APPC125) as described previously (27). Briefly, assays were carried out in 20 mM sodium acetate, pH 4.8, 0.06% Triton X-100, with 10 µg/ml MBP-APPC125. Reaction mixtures were diluted 1:5, incubated at 37 °C for 2 h, and the quenched reaction mixtures were then loaded onto 96-well plates coated with a polyclonal antibody raised to MBP. Cleaved products were detected using biotinylated Sw192 as specific reporter antibodies, and purified hBACE1 was used as a standard for both activity assays.



View larger version (29K):
[in this window]
[in a new window]
  		FIGURE 2.
Decreases in FL APP and increases in APP CTFs in hBACE1 tg mice. Homogenates of frontal cortex from 6-month-old hBACE1 tg mice and non-tg littermates were separated into cytosolic and particulate fractions and analyzed by Western blotting with antibodies against FL APP (22C11, mouse monoclonal), APP CTFs (CT15, rabbit polyclonal), and actin (mouse monoclonal), and expression levels were quantitated. A, representative Western blot of samples from different hBACE1 tg lines. Each lane contains a sample from a different mouse. B and C, quantitation of Western blot bands (n = 4 mice/genotype). D–I, double immunolabeling and confocal microscopic analysis of hBACE1 (red) and APP CTFs (green) in the frontal cortex of 6-month-old non-tg (D–F) and hBACE1 tg (G–I) mice. Bar = 20 µm. *, p < 0.05 versus non-tg controls (Dunnett's t test).

 
Behavioral Analysis—Mice had free access to food and water, and all experiments were carried out during the light cycle. Experimental and control groups contained similar proportions of males and females. The water maze test was carried out as described previously (28). Briefly, a pool (diameter 180 cm) was filled with opaque water (24 °C) and mice were first trained to locate a visible platform (days 1–3) and then a submerged hidden platform (days 4–7) in three daily trials 2–3 min apart. Mice that failed to find the hidden platform within 90 s were placed on it for 30 s. The same platform location was used for all sessions and all mice. The starting point at which each mouse was placed into the water was changed randomly between two alternative entry points located at a similar distance from the platform. On day 8, another visible platform trial was performed to exclude differences in motivation and fatigue. Time to reach the platform (latency), path length, and swim speed were recorded with a Noldus Instruments EthoVision video tracking system (San Diego Instruments, San Diego) set to analyze two samples/s.

Immunohistochemistry—Vibratome sections (40 µm) of brain tissues were incubated overnight at 4 °C with primary antibodies against hBACE1 (ProSci, Inc.; 1:500) or hAPP (8E5; Elan; 1:20,000, TABLE ONE). Binding of primary antibody was detected with the Vector ABC Elite kit (Vector Laboratories, Burlingame, CA), diaminobenzidine tetrahydrochloride, and 0.001% H2O2. Double labeling studies were performed essentially as described previously (28). Briefly, vibratome sections were incubated overnight at 4 °C with anti-hBACE1 (1:500) and developed with the Tyramide Signal Amplification-Direct (Red) system (PerkinElmer Life Sciences; 1:100). Sections were then incubated overnight with an antibody against APP CTFs (CT15; 1:100), followed by incubation with FITC-tagged secondary goat anti-rabbit (Vector; 1:75) and imaging by laser scanning confocal microscopy (LSCM, MRC 1024, Bio-Rad).

Neuropathological Analysis—Vibratome sections were incubated overnight at 4 °C with mouse monoclonal antibodies against the neuronal dendritic marker microtubule-associated protein 2 (MAP2; Chemicon; 1:100), the axonal neurofilament marker SMI312 (Sternberger Immuocytochemicals, Baltimore, MD; 1:200), or the astroglial marker glial fibrillary acidic protein (GFAP; Chemicon; 1:500) as described previously (29). Binding of primary antibodies was detected with the Vector Elite kit and diaminobenzidine tetrahydrochloride/H2O2, or with FITC-conjugated IgG secondary antibodies (Vector; 1:75). Immunoperoxidase-labeled sections were examined with an Olympus Vanox light microscope. FITC-labeled sections were analyzed by confocal microscopy (29, 30).

For ultrastructural analysis, blocks of neocortex and hippocampus were postfixed with 2% glutaraldehyde and 0.1% osmium tetroxide in 0.1 M sodium cacodylate buffer and embedded in epoxy. Blocks were sectioned with an Ultracut E ultramicrotome (Leica, Nussloch, Germany) and analyzed with a Zeiss EM10 electron microscope (Carl Zeiss, Oberkochen, Germany) (31).

Statistical Analysis—Analyses were carried out with the StatView 5.0 program (SAS Institute Inc., Cary, NC). Differences among means were assessed by student's t test or by one-way ANOVA followed by Dunnett's or Tukey-Kramer post hoc tests as indicated. Learning curves were analyzed by repeated measures ANOVA. The null hypothesis was rejected at the 0.05 level.



View larger version (40K):
[in this window]
[in a new window]
  		FIGURE 3.
Decreases in FL APP and increases in APP CTFs in hBACE1/hAPP tg mice. Homogenates of frontal cortex from 6-month-old hBACE1 tg, hAPP tg, hBACE1/hAPP doubly tg mice, and non-tg littermates were separated into cytosolic and particulate fractions and analyzed by Western blotting with antibodies against FL APP (22C11, mouse monoclonal), APP CTFs (CT15, rabbit polyclonal), and actin (mouse monoclonal), and expression levels were quantitated. A, representative Western blot of samples from hBACE1/hAPP doubly tg mice and singly tg hBACE1 and hAPP controls. B and C, quantitation of Western blot bands (n = 4 mice/group). D–I, double immunolabeling and confocal microscopic analysis of hBACE1 (red) and hAPP (green) in the frontal cortex of 6-month-old hAPP tg (D–F) and hBACE1/hAPP tg (G–I) mice. Bar = 20 µm. *, p < 0.05 versus non-tg controls (Dunnett's t test); **, p < 0.05 versus hBACE1/hAPP doubly tg mice (Tukey-Kramer test).

 

   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Expression of BACE1 in Brains of mThy1-hBACE1 tg Mice—Micro-injection of the mThy1-hBACE1 construct yielded four tg lines, three of which were selected for further analysis based on levels of hBACE1 mRNA determined by RPA. hBACE1 mRNA levels in whole hemibrains of these tg lines were 3–8-fold higher than in frontal cortex of humans without AD, with the highest levels detected in line 1 (Fig. 1, A and B). In all three lines, levels of endogenous mBACE1 were decreased by 30–50% compared with non-tg controls (Fig. 1C). Consistent with the mRNA analysis, hBACE1 protein levels (Fig. 1, D and E), hBACE activity (Fig. 1F), and neuronal hBACE1 immunoreactivity (Fig. 1, G–J) were higher in line 1 than in lines 2 and 39. In all three lines, high levels of hBACE1 immunoreactivity were observed in pyramidal neurons in layers 4–5 of the neocortex (Fig. 1, H–J). In the hippocampal formation, hBACE1 immunoreactivity was detected in pyramidal cells of the CA1 region and in granule cells of the dentate gyrus in line 1, and in pyramidal neurons of CA1–3, but not in granule cells, in lines 2 and 39 (not shown). Moderate hBACE1 immunoreactivity was also detected in subcortical nuclei and the cerebellum of all three lines (not shown). In brains of non-tg controls, no immunoreactivity above background levels was detected with the hBACE1-specific antibody (Fig. 1, D, E, and G).

High Levels of hBACE1 Expression Increase APP CTFs but Decrease Levels of Full-length APP and A{beta}—Full-length (FL) APP was detected on Western blots of brain homogenates as a triple band (Fig. 2A). Compared with non-tg controls, high expresser hBACE1 tg mice had decreased levels of FL APP (Fig. 2A and B); this decrease was most marked in the two upper bands. In contrast, levels of APP CTFs were 2–3-fold higher in hBACE1 mice than in non-tg controls, as determined by Western blot analysis with the CT15 antibody, which recognizes the hBACE1-generated C89 and C99 fragments of APP (Fig. 2, A and C), as well as the {alpha}-secretase-generated C83 fragment (32). Double labeling analysis confirmed that intraneuronal accumulation of APP CTFs was higher in hBACE1 mice than in non-tg controls (Fig. 2, D–I). Moreover, neurons displaying the highest levels of hBACE1 expression also showed the highest levels of APP CTF immunoreactivity (Fig. 2, G–I). To further characterize the effects of high levels of hBACE1 expression on hAPP processing, homogenates from hAPP singly tg mice expressing a familial AD-mutant hAPP (line 41 (23)) and hBACE1(line 1)/hAPP(line 41) doubly tg mice were analyzed by Western blot. Singly tg hAPP mice showed an increase in overall levels of cerebral APP expression compared with non-tg controls (Fig. 3, A–C). Compared with these mice, hBACE1/hAPP mice had lower levels of FL APP and higher levels of APP CTFs (Fig. 3, A–C). Immunoreactivities for hBACE1 and APP CTFs in hBACE1/hAPP mice were colocalized in the same neurons (Fig. 3, G–I), consistent with the notion that the increase in APP CTFs resulted from increased cleavage of hAPP by hBACE1.

To investigate APP metabolism in greater detail in these mice, APP CTFs were detected by immunoblot analysis after separation on Tricine/SDS-polyacrylamide gels. This analysis revealed that the increase in APP CTFs in hBACE1/hAPP mice represents primarily an accumulation of C89, which results from APP cleavage at the {beta}' site (Fig. 4A). Whereas {gamma}-secretase cleavage of C99 would result in the production of A{beta}1–x, {gamma}-secretase cleavage of C89 would result in the production of A{beta}11–x. Surprisingly, hBACE1/hAPP mice had decreased levels of both A{beta}1–x and truncated A{beta} species. Hippocampal levels of A{beta}1–x (Fig. 4B) and A{beta}1–42 (Fig. 4C) were much lower in hBACE1/hAPP mice than in hAPP singly tg mice. Because the ELISAs used to obtain these measurements specifically detect peptides containing the first five amino acids of A{beta}, we also analyzed A{beta} levels with antibody 266, which was raised against the middle portion of the A{beta} peptide (amino acids 13–28, TABLE ONE) (25). Extraction of hippocampal proteins with formic acid, followed by high resolution acid urea-PAGE and Western blot analysis with the 266 antibody, confirmed reductions in all detectable A{beta} species in hBACE1/hAPP mice compared with hAPP singly tg mice (Fig. 4D). Consistent with these biochemical data, amyloid plaques were detected at 3 and 6 months of age in the frontal cortex and hippocampus in hAPP mice but not in hBACE1/hAPP mice (Fig. 4, E and F, and data not shown).



View larger version (59K):
[in this window]
[in a new window]
  		FIGURE 4.
Accumulation of APP CTFs and decreases in the levels and deposition of A{beta} in hBACE1/hAPP doubly tg mice. Homogenates of frontal cortex from 3- to 5-month-old singly tg mice from hAPP line 41 and hBACE1 line 1, doubly tg hBACE1/hAPP mice, and non-tg controls were separated by differential centrifugation, and the particulate fractions were separated on 14% Tricine gels and analyzed by Western blotting with an antibody against APP CTFs (CT15, rabbit polyclonal). A, representative Western blot of samples from hAPP and hBACE1/hAPP doubly tg mice. To confirm that this approach can detect differences in the relative abundance of different APP CTFs, we included samples from the hippocampus of two previously characterized PDGF-hAPP tg lines expressing comparable levels of familial AD-mutant (J20) or wild-type (I5) hAPP (29). Consistent with known effects of the Swedish mutation on APP cleavage by BACE1, the J20 mouse had more C99 than C83 fragments, whereas the I5 mouse had mostly C83. B and C, hippocampal levels of A{beta}1–x (B) and A{beta}1–42 (C) in 5-month-old mice (n = 6–7 mice/line) were determined by ELISA. D, A{beta}1–42, A{beta}1–40, and A{beta}1–38 species were detected by high resolution acid urea-PAGE and Western blot analysis with the 266 antibody as described previously (25). Each lane contained proteins extracted from the neocortex (1 mg/lane) of a different mouse. E and F, A{beta} deposits were detected in hippocampal vibratome sections by immunostaining with the 4G8 antibody. By 3 months of age, hAPP tg mice from line 41 had amyloid deposits (E), whereas hBACE1/hAPP tg mice did not (F). G, comparison of the levels of neprilysin, IDE, and Notch between non-tg controls and hAPP, hBACE1, and hBACE1/hAPP tg mice by Western blot analysis. Levels of actin immunoreactivity were used as the loading control. Homogenates were from the frontal cortex of 6-month-old mice. H, quantitative analysis of levels of neprilysin, IDE, and Notch expression. I, analysis of phosphorylated FL APP (APP-p) and phosphorylated APP CTFs (C99-p, C89-p, C83-p) in hAPP and hBACE1/hAPP tg mice. Homogenates from the frontal cortex of 6-month-old mice were separated on polyacrylamide-Tricine gels, transferred to nitrocellulose, and probed with the APP-p (Thr-668) antibody. J, quantitative analysis showing that levels of APP-p, C99-p, and C83-p were reduced in the bigenic mice. *, p < 0.05 versus hAPP tg mice (unpaired two-tailed Student's t test).

 



View larger version (17K):
[in this window]
[in a new window]
  		FIGURE 5.
Learning deficits in hBACE1 and hBACE1/hAPP tg mice. At 6 months of age, hBACE1 (line 39), hAPP mice (line 41), hBACE1/hAPP mice, and non-tg littermates (n = 8 mice/group) mice were trained in a Morris water maze to locate a visible platform (days 1–3), then a submerged platform (days 4–7), and once again a visible platform (day 8). By day 3 of the cued component of this test (platform visible), all four groups achieved a comparable escape latency. When the platform was hidden, all three groups of tg mice showed significant learning deficits compared with non-tg controls (p < 0.05 for days 5–7, p > 0.1 for days 1–3 for each of the tg groups by repeated measures ANOVA). A trend toward more severe deficits was observed in the hBACE1/hAPP mice, but by repeated measures ANOVA the curves for the hidden platform were not different among the three groups of tg mice. However, on the last day of hidden platform testing (day 7), hBACE1/hAPP mice performed more poorly than hBACE1 mice and hAPP tg mice (p < 0.05 by one way ANOVA).

 
These findings raise the possibilities that the decreased levels of A{beta}1–x and A{beta}1–42 result from alterations in the activity of {gamma}-secretase, in the availability of its substrate, or in the rate of A{beta} turnover by enzymes such as neprilysin and insulin-degrading enzyme (IDE). Immunoblot analysis with antibodies against neprilysin or IDE showed roughly comparable levels of these enzymes in hBACE1 mice, hAPP mice, hBACE1/hAPP mice, and non-tg controls (Fig. 4, G and H). In addition, levels of Notch, another {gamma}-secretase substrate, were comparable among the four groups of mice (Fig. 4, G and H). These results suggest that the decrease in A{beta} levels in mice with high levels of hBACE1 activity does not result from increased degradation of A{beta} or decreased {gamma}-secretase activity.

Similar decreases in A{beta} in an independent line of hBACE1 tg mice have recently been related to decreased availability of mature phosphorylated APP (APP-p) (19). Consistent with this possibility, Western blot analysis with an antibody against APP-p-threonine 668 revealed that the cerebral levels of FL APP-p and C99-p were lower in hBACE1/hAPP mice than in hAPP mice (Fig. 4, I and J). These results support the notion that high levels of hBACE1 activity increase hAPP cleavage in the early secretory pathway, depleting mature hAPP-p before it is transported to the axon terminals, where a large proportion of A{beta} generation by the {gamma}-secretase complex takes place (19).

Increased Activity of hBACE1 Elicits Learning Deficits and Neurodegenerative Alterations—At 3 months of age, hBACE1 tg mice from the highest expresser line 1 showed mild weakness and spasticity of the hind limbs. This phenotype was more apparent at 6 months and progressed to a prominent spastic paraparesis by 12 months of age. hBACE1 mice from the intermediate expresser lines 2 and 39 showed no obvious neurological deficits when inspected at 3 and 6 months of age, although at 12 months they had a mild tremor.

Because hBACE1 tg mice from line 1 developed age-dependent neurological deficits that precluded assessment in the water maze test, hBACE1 tg mice from line 39 were selected for crosses with hAPP tg mice for behavioral analysis. At 6 months of age, hBACE1 mice from line 39, hAPP mice, hBACE1/hAPP mice, and non-tg littermates were tested in the Morris water maze to examine their spatial learning and memory. By day 3 of the cued component of this test (platform visible), all four groups achieved similar escape latencies (Fig. 5). When the platform was hidden, all three groups of tg mice showed significant learning deficits compared with non-tg controls (Fig. 5). A trend toward more severe deficits was observed in the hBACE1/hAPP mice, but by repeated measures ANOVA the curves for the hidden platform were not different among the three groups of tg mice. However, on the last day of the test (day 7) the performance deficits of the hBACE1/hAPP group were significantly different (one way ANOVA, p < 0.05) compared with the hBACE1 and hAPP tg mice.

To assess the extent of neurodegenerative alterations in hBACE1 mice, immunolabeling was performed with antibodies against markers of neuronal and dendritic integrity. Compared with non-tg controls (Fig. 6A), mice expressing high levels of hBACE1 displayed shrinkage of pyramidal neurons in the CA3 region of the hippocampus (Fig. 6B), with the worst alterations seen in mice from the highest expresser line 1 (Fig. 6, B and C). Compared with non-tg controls (Fig. 6D), pyramidal neurons in layers 2–3 of the neocortex were also shrunken and condensed in all three hBACE1 tg lines (Fig. 6, E and F). In contrast to the normal labeling of neurites with antibodies against neurofilament (Fig. 6G) and MAP2 (Fig. 6J) in non-tg controls, axonal and dendritic processes of pyramidal neurons in hBACE1 mice were diminished, disrupted, and vacuolized (Fig. 6, H and K). These alterations were prominent at 12 months (Fig. 6, I and L) and detectable, albeit to lesser extent, at 3 and 6 months of age (not shown). At 12 months of age, the neurodegenerative alterations in hBACE1 tg mice were associated with a reactive astrocytosis (Fig. 6N) not observed in non-tg controls (Fig. 6, M and O). In contrast to non-tg littermate controls (Fig. 6P), hBACE1 mice from line 1 showed collapsed neuronal cytoplasm, accumulations of electrodense material, extensive vacuolization of dendritic arbors (Fig. 6Q), and wide-spread degeneration of axonal processes with splinting and disorganization of myelin laminations (Fig. 6R). Significant loss and alterations of neuritic structures were also detected in hAPP singly tg mice, but only hBACE1 mice and hBACE1/hAPP mice had considerable damage also in the CA3 region of the hippocampus (Fig. 7). Compared with non-tg controls (Fig. 7A), hAPP (Fig. 7B) and hBACE1 (Fig. 7C) mice had reduced levels of MAP2 immunoreactivity in the frontal cortex, an alteration that was even more prominent in hBACE1/hAPP mice (Fig. 7E). In the CA3 region of the hippocampus, all three tg groups showed a loss of dendritic complexity, which was most severe in hBACE1 and hBACE1/hAPP mice (Fig. 7, F–J).


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
The present study demonstrates that increased activity of hBACE1 in neurons of tg mice is sufficient to elicit profound alterations in APP metabolism, neurological deficits, and neurodegeneration. Although BACE1 is required for the generation of A{beta}, high levels of neuronal hBACE1 activity decreased rather than increased A{beta} levels in hBACE1/hAPP mice compared with hAPP singly tg mice, suggesting that A{beta} was not the main mediator of the increased neuronal deficits identified in the doubly tg mice. Because APP-deficient mice (33, 34) do not show the neurological and neuropathological alterations we observed in several lines of hBACE1 tg mice, it is also unlikely that the decrease in FL or {alpha}-secretase-processed APP accounts for the neuronal deficits seen in hBACE1 tg mice. A likelier pathogenic mechanism involves the accumulation of APP CTFs and/or the mismetabolism of alternative hBACE1 substrates.

hBACE1 cleaves APP at two sites ({beta} and {beta}') generating the classical C-terminal stub (C99) and the alternative C89 fragment (15, 35). Although most of the current research in AD is focused on the potential neurotoxic effects of A{beta}, APP CTFs have also been shown to have deleterious effects. For example, in primary neuronal cultures, accumulation of the C99 fragment promotes apoptosis (36); tg mice overexpressing CTFs in neurons develop hippocampal degeneration as well as deficits in memory and long term potentiation (36–39).




View larger version (135K):
[in this window]
[in a new window]
  		FIGURE 6.
Neuropathological and ultrastructural alterations in the brains of hBACE1 tg mice. Vibratome sections from 6-month-old mice were either stained with cresyl violet (A–F), immunostained with antibodies against neurofilaments (G–I), MAP2 (J–L) or GFAP (M–O), or processed for electron microscopy (P–R). For A and B, representative images are from the hippocampus, and for D–O, images are from the neocortex of non-tg and hBACE1 tg (line 1) mice. A and B, neuronal shrinkage and degeneration (arrows) in the CA3 region of an hBACE1 tg mouse. C, quantitative assessment of the cell density in CA3 revealing significant loss of neurons in mice from lines 1 and 2 (n = 6 mice/group). D and E, neuronal shrinkage and degeneration (arrows) in layers II–III of the fronto-parietal region in an hBACE1 tg mouse. F, quantitative assessment of the cell density in the neocortex revealing significant loss of neurons in mice from line 1 (n = 6 mice/group). G and H, loss of phosphorylated high and intermediate molecular mass neurofilaments in an hBACE1 tg mouse, as revealed by immunostaining with SMI312 (mouse monoclonal) and bright field microscopy. I, quantitation of SMI312 immunoreactivity showing a significant decrease in all three lines of hBACE1 tg mice (n = 6 mice/group). J and K, alterations of MAP2-positive neuronal and dendritic structures in an hBACE1 tg mouse, as demonstrated by LSCM. L, quantitative assessment of percent area of the neocortex occupied by MAP2-immunoreactive dendrites in the neocortex revealing significant losses in all lines of hBACE1 tg mice (n = 6 mice/group). M and N, reactive astrocytosis in an hBACE1 tg mouse, as revealed by GFAP immunostaining and bright field microscopy. O, quantitation of GFAP immunoreactivity in the neocortex showing a significant increase in hBACE1 tg mice from line 1 (n = 6 mice/group). P, ultrastructural analysis demonstrating well preserved neuronal (n), dendritic, and axonal structures in a non-tg mouse. Q, in contrast, an hBACE1 tg mouse from line 1 showed considerable neuronal shrinkage, condensation, and vacuolization of dendrites (d). R, axon (a) in an hBACE1 mouse showing thinning and degeneration of myelin sheaths. Bars = 25 µm(A, B, D, E, G, H, M, and N), 15 µm(J and K), 3 µm(P and Q), and 2 µm(R). *, p < 0.05 versus non-tg controls (Dunnett's t test).

 



View larger version (52K):
[in this window]
[in a new window]
  		FIGURE 7.
Neurodegenerative alterations in hBACE1/hAPP tg mice. Sections from the brains of 6-month-old mice were immunolabeled with an antibody against MAP2 (mouse monoclonal) and imaged with the LSCM. A–D are from the frontal cortex, and F–I are from the hippocampus (Hipp). Although neurons and dendrites were well preserved in non-tg controls (A and F), there was evidence for neurodegeneration in hAPP tg (B and G) and hBACE1 tg (C and H) mice. Neurodegenerative alterations were even more severe in hBACE1/hAPP tg mice (D and I). E and J, quantitation of the percent area of the neuropil covered by MAP2-immunoreactive dendrites revealed significant depletion of MAP2-positive neuronal structures in hBACE1 tg lines. Bar = 15 µm. *, p < 0.05 versus non-tg controls (Dunnett's t test).

 
Increased activity of hBACE1 led to an increase in the levels of APP CTFs in both hBACE1 mice and hBACE1/hAPP mice, consistent with previous observations (19–21, 40, 41). Moreover, the levels of APP CTFs in different lines of hBACE1 mice were related to the extent of neurological and neuropathological alterations: the highest levels of APP CTFs were found in the most severely impaired line 1. Although previous studies (19–21, 40, 41) have shown an increase in C99 and C89 and a decrease in C83, in the present study we found that the most significant increase was in levels of C89, whereas C83 levels were decreased. This suggests that in our model APP processing may occur preferentially at the {beta}' cleavage site (15, 35). Interestingly, despite an overall increase in C99 and C89 in previous studies, levels of C99-p were decreased significantly in hBACE1/hAPP mice, and this decrease in C-99 phosphorylation was more apparent in mice expressing higher levels of hBACE1 (19). Compared with hAPP tg mice, our hBACE1/hAPP mice showed lower levels of C99, and C99-p was decreased with hBACE1 overexpression. Because phosphorylation of APP is a post-translational modification necessary for maturation and axonal transport of C99 (42, 43), the decrease in C99-p indicates that APP cleavage in the hBACE1/hAPP mice might occur in early compartments (19).

High levels of hBACE1 and APP CTFs in our hBACE1/hAPP mice were associated with decreased levels of human A{beta}1–x and A{beta}1–42, as determined by highly quantitative ELISA measurements. These results are consistent with a recent study (19) but differ from results obtained in other hBACE1/hAPP models (20, 21, 40, 41). Several factors might account for these differences, including the genetic background of the mice analyzed. However, the most critical factor in determining the effects of hBACE1 activity might be the levels of hBACE1 transgene expression (19). Although low and intermediate levels of hBACE1 expression enhanced amyloid production and deposition in doubly tg mice, higher levels of hBACE1 expression reduced A{beta} production, presumably because high levels of hBACE1 activity shifted the subcellular location of APP cleavage to the neuronal cell body and early secretory pathway, resulting in a depletion of mature APP-p in the trans-Golgi compartment (19). Thus, a lesser amount of APP might be targeted to the distal axon, which would preclude {gamma}-secretase-mediated generation of A{beta} at synaptic sites.

If not A{beta}, what other factors may result in the degeneration of neurons with high levels of BACE1 activity? Recent evidence suggests that the toxicity of CTFs may be mediated by the caspase-generated C-terminal C31 fragment (44, 45). It will therefore be interesting to test whether preventing the generation of C31 prevents neurodegeneration in hBACE1/hAPP mice. In a similar vein, expression of hBACE1 in mAPP-deficient mice might reveal APP-independent mechanisms of hBACE1-induced neurotoxicity. Conceivably, increased BACE1 activity might trigger neurodegeneration by cleavage of substrates other than APP. For example, both in vitro (12) and in vivo (46) BACE1 cleaves ST6Gal I, a sialyltransferase whose cleavage product is secreted. Recently, it has been shown that BACE1 also cleaves {beta}-subunits of voltage-gated sodium channels (47). Increased levels of hBACE1 activity could further broaden the substrate specificity of this enzyme in both tg mice and humans with AD.

Indeed, recent studies have identified increased levels of hBACE1 immunoreactivity and of APP CTFs in AD brains (14–17), suggesting that increased BACE1 activity may be causally involved also in the pathogenesis of AD. The current study supports and extends this notion by demonstrating that increased neuronal hBACE1 activity can cause progressive neurodegenerative alterations in vivo. Whereas inhibiting {gamma}-secretase, which does not alter {alpha}- or {beta}-secretase processing, decreases A{beta} production but increases the accumulation of APP CTFs (48, 49), inhibiting BACE1 may block both A{beta}-dependent and A{beta}-independent pathogenic mechanisms in AD.


   FOOTNOTES
 
* This work was supported by National Institutes of Health Grants AG18440, AG10869, AG5131, and AG022074. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 To whom correspondence should be addressed: Dept. of Neurosciences, University of California, San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0624. Tel.: 858-534-8992; Fax: 858-534-6232; E-mail: emasliah{at}ucsd.edu.

2 The abbreviations used are: AD, Alzheimer disease; A{beta} peptide, amyloid-{beta} peptide; ANOVA, analysis of variance; APP, amyloid precursor protein; BACE1, {beta}-site APP-cleaving enzyme; CTF, C-terminal fragment; ELISA, enzyme-linked immunosorbent assay; FITC, fluorescein isothiocyanate; FL, full-length; FRET, fluorescence resonance energy transfer; GFAP, glial fibrillary acidic protein; h, human; IDE, insulin-degrading enzyme; LSCM, laser scanning confocal microscopy; m, mouse; MAP2, microtubule-associated protein 2; MBP, maltose-binding protein; -p, phosphorylated; RPA, ribonuclease protection assay; Sw, Swedish; tg, transgenic; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine. Back


   ACKNOWLEDGMENTS
 
We thank Dr. H. van der Putten for providing the mThy1 cassette, Dr. E. Koo for the CT15 antibody, Dr. Lisa McConlogue for the hBACE antibody and activity assay, and Dr. P. Seubert for the 8E5 antibody.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Sinha, S., Anderson, J., John, V., McConlogue, L., Basi, G., Thorsett, E., and Schenk, D. (2000) Ann. N. Y. Acad. Sci. 920, 206-208[Free Full Text]
  2. Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., and Malinow, R. (2003) Neuron 37, 925-937[CrossRef][Medline] [Order article via Infotrieve]
  3. Selkoe, D. J., and Schenk, D. (2003) Annu. Rev. Pharmacol. Toxicol. 43, 545-584[CrossRef][Medline] [Order article via Infotrieve]
  4. Selkoe, D. J. (1999) Nature 399, (Suppl. 6738) Abstr. 23-31
  5. Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M., Dovey, H. F., Frigon, N., Hong, J., Jacobson-Croak, K., Jewett, N., Keim, P., Knops, J., Lieberburg, I., Power, M., Tan, H., Tatsuno, G., Tung, J., Schenk, D., Seubert, P., Suomensaari, S. M., Wang, S., Walker, D., and John, V. (1999) Nature 402, 537-540[CrossRef][Medline] [Order article via Infotrieve]
  6. Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jarosinski, M. A., Biere, A. L., Curran, E., Burgess, T., Louis, J. C., Collins, F., Treanor, J., Rogers, G., and Citron, M. (1999) Science 286, 735-741[Abstract/Free Full Text]
  7. Cai, H., Wang, Y., McCarthy, D., Wen, H., Borchelt, D. R., Price, D. L., and Wong, P. C. (2001) Nat. Neurosci. 4, 233-234[CrossRef][Medline] [Order article via Infotrieve]
  8. Luo, Y., Bolon, B., Kahn, S., Bennett, B. D., Babu-Khan, S., Denis, P., Fan, W., Kha, H., Zhang, J., Gong, Y., Martin, L., Louis, J. C., Yan, Q., Richards, W. G., Citron, M., and Vassar, R. (2001) Nat. Neurosci. 4, 231-232[CrossRef][Medline] [Order article via Infotrieve]
  9. Citron, M. (2002) Neurobiol. Aging 23, 1017-1022[CrossRef][Medline] [Order article via Infotrieve]
  10. Xia, W. M., and Wolfe, M. S. (2003) J. Cell Sci. 116, 2839-2844[Abstract/Free Full Text]
  11. Asai, M., Hattori, C., Szabó, B., Sasagawa, N., Maruyama, K., Tanuma, S., and Ishiura, S. (2003) Biochem. Biophys. Res. Commun. 301, 231-235[CrossRef][Medline] [Order article via Infotrieve]
  12. Kitazume, S., Tachida, Y., Oka, R., Shirotani, K., Saido, T. C., and Hashimoto, Y. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 13554-13559[Abstract/Free Full Text]
  13. Kirschling, C. M., Kölsch, H., Frahnert, C., Rao, M. L., Maier, W., and Heun, R. (2003) Neuroreport 14, 1243-1246[CrossRef][Medline] [Order article via Infotrieve]
  14. Holsinger, R. M., McLean, C. A., Beyreuther, K., Masters, C. L., and Evin, G. (2002) Ann. Neurol. 51, 783-786[CrossRef][Medline] [Order article via Infotrieve]
  15. Huse, J. T., Liu, K., Pijak, D. S., Carlin, D., Lee, V. M., and Doms, R. W. (2002) J. Biol. Chem. 277, 16278-16284[Abstract/Free Full Text]
  16. Rossner, S., Apelt, J., Schliebs, R., Perez-Polo, J. R., and Bigl, V. (2001) J. Neurosci. Res. 64, 437-446[CrossRef][Medline] [Order article via Infotrieve]
  17. Fukumoto, H., Cheung, B. S., Hyman, B. T., and Irizarry, M. C. (2002) Arch. Neurol. 59, 1381-1389[Abstract/Free Full Text]
  18. Li, R., Lindholm, K., Yang, L. B., Yue, X., Citron, M., Yan, R., Beach, T., Sue, L., Sabbagh, M., Cai, H., Wong, P., Price, D., and Shen, Y. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 3632-3637[Abstract/Free Full Text]
  19. Lee, E. B., Zhang, B., Liu, K., Greenbaum, E. A., Doms, R. W., Trojanowski, J. Q., and Lee, V. M. (2005) J. Cell Biol. 168, 291-302[Abstract/Free Full Text]
  20. Bodendorf, U., Danner, S., Fischer, F., Stefani, M., Sturchler-Pierrat, C., Wiederhold, K. H., Staufenbiel, M., and Paganetti, P. (2002) J. Neurochem. 80, 799-806[CrossRef][Medline] [Order article via Infotrieve]
  21. Chiocco, M. J., Kulnane, L. S., Younkin, L., Younkin, S., Evin, G., and Lamb, B. T. (2004) J. Biol. Chem. 279, 52535-52542[Abstract/Free Full Text]
  22. Harrison, S. M., Harper, A. J., Hawkins, J., Duddy, G., Grau, E., Pugh, P. L., Winter, P. H., Shilliam, C. S., Hughes, Z. A., Dawson, L. A., Gonzalez, M. I., Upton, N., Pangalos, M. N., and Dingwall, C. (2003) Mol. Cell. Neurosci. 24, 646-655[CrossRef][Medline] [Order article via Infotrieve]
  23. Rockenstein, E., Mallory, M., Hashimoto, M., Song, D., Shults, C. W., Lang, I., and Masliah, E. (2002) J. Neurosci. Res. 68, 568-578[CrossRef][Medline] [Order article via Infotrieve]
  24. Rockenstein, E., McConlogue, L., Tan, H., Power, M., Masliah, E., and Mucke, L. (1995) J. Biol. Chem. 270, 28257-28267[Abstract/Free Full Text]
  25. DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J. C., Paul, S. M., and Holtzman, D. M. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 8850-8855[Abstract/Free Full Text]
  26. Johnson-Wood, K., Lee, M., Motter, R., Hu, K., Gordon, G., Barbour, R., Khan, K., Gordon, M., Tan, H., Games, D., Lieberburg, I., Schenk, D., Seubert, P., and McConlogue, L. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 1550-1555[Abstract/Free Full Text]
  27. Roberds, S. L., Anderson, J., Basi, G., Bienkowski, M. J., Branstetter, D. G., Chen, K. S., Freedman, S. B., Frigon, N. L., Games, D., Hu, K., Johnson-Wood, K., Kappenman, K. E., Kawabe, T. T., Kola, I., Kuehn, R., Lee, M., Liu, W., Motter, R., Nichols, N. F., Power, M., Robertson, D. W., Schenk, D., Schoor, M., Shopp, G. M., Shuck, M. E., Sinha, S., Svensson, K. A., Tatsuno, G., Tintrup, H., Wijsman, J., Wright, S., and McConlogue, L. (2001) Hum. Mol. Genet. 10, 1317-1324[Abstract/Free Full Text]
  28. Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M., and Mucke, L. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 12245-12250[Abstract/Free Full Text]
  29. Mucke, L., Yu, G. Q., McConlogue, L., Rockenstein, E. M., Abraham, C. R., and Masliah, E. (2000) Am. J. Pathol. 157, 2003-2010[Abstract/Free Full Text]
  30. Mucke, L., Masliah, E., Yu, G. Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., and McConlogue, L. (2000) J. Neurosci. 20, 4050-4058[Abstract/Free Full Text]
  31. Rockenstein, E., Mallory, M., Mante, M., Sisk, A., and Masliah, E. (2001) J. Neurosci. Res. 66, 573-582[CrossRef][Medline] [Order article via Infotrieve]
  32. Oltersdorf, T., Ward, P. J., Henriksson, T., Beattie, E. C., Neve, R., Lieberburg, I., and Fritz, L. C. (1990) J. Biol. Chem. 265, 4492-4497[Abstract/Free Full Text]
  33. Zheng, H., Jiang, M., Trumbauer, M. E., Hopkins, R., Sirinathsinghji, D. J., Stevens, K. A., Conner, M. W., Slunt, H. H., Sisodia, S. S., Chen, H. Y., and Van der Ploeg, L. H. (1996) Ann. N. Y. Acad. Sci. 777, 421-426[Abstract]
  34. Masliah, E., and Rockenstein, E. (2000) J. Neural Transm. Suppl. 59, 175-183[Medline] [Order article via Infotrieve]
  35. Huse, J. T., Pijak, D. S., Leslie, G. J., Lee, V. M., and Doms, R. W. (2000) J. Biol. Chem. 275, 33729-33737[Abstract/Free Full Text]
  36. Kim, H. S., Park, C. H., Cha, S. H., Lee, J. H., Lee, S., Kim, Y., Rah, J. C., Jeong, S. J., and Suh, Y. H. (2000) FASEB J. 14, 1508-1517[Abstract/Free Full Text]
  37. Song, D. K., Won, M. H., Jung, J. S., Lee, J. C., Kang, T. C., Suh, H. W., Huh, S. O., Paek, S. H., Kim, Y. H., Kim, S. H., and Suh, Y. H. (1998) J. Neurochem. 71, 875-878[Medline] [Order article via Infotrieve]
  38. Oster-Granite, M., McPhie, D., Greenan, J., and Neve, R. (1996) J. Neurosci. 16, 6732-6741[Abstract/Free Full Text]
  39. Berger-Sweeney, J., McPhie, D. L., Arters, J. A., Greenan, J., Oster-Granite, M. L., and Neve, R. L. (1999) Mol. Brain Res. 66, 150-162[Medline] [Order article via Infotrieve]
  40. Mohajeri, M. H., Saini, K. D., and Nitsch, R. M. (2004) J. Neural. Transm. 111, 413-425[CrossRef][Medline] [Order article via Infotrieve]
  41. Willem, M., Dewachter, I., Smyth, N., Van Dooren, T., Borghgraef, P., Haass, C., and Van Leuven, F. (2004) Am. J. Pathol. 165, 1621-1631[Abstract/Free Full Text]
  42. Ando, K., Oishi, M., Takeda, S., Iijima, K., Isohara, T., Nairn, A. C., Kirino, Y., Greengard, P., and Suzuki, T. (1999) J. Neurosci. 19, 4421-4427[Abstract/Free Full Text]
  43. Iijima, K., Ando, K., Takeda, S., Satoh, Y., Seki, T., Itohara, S., Greengard, P., Kirino, Y., Nairn, A. C., and Suzuki, T. (2000) J. Neurochem. 75, 1085-1091[CrossRef][Medline] [Order article via Infotrieve]
  44. Koo, E., Lansbury, P. J., and Kelly, J. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 9989-9990[Free Full Text]
  45. Bredesen, D. (1995) Ann. Neurol. 38, 839-851[CrossRef][Medline] [Order article via Infotrieve]
  46. Kitazume, S., Nakagawa, K., Oka, R., Tachida, Y., Ogawa, K., Luo, Y., Citron, M., Shitara, H., Taya, C., Yonekawa, H., Paulson, J. C., Miyoshi, E., Taniguchi, N., and Hashimoto, Y. (2005) J. Biol. Chem. 280, 8589-8595[Abstract/Free Full Text]
  47. Wong, H. K., Sakurai, T., Oyama, F., Kaneko, K., Wada, K., Miyazaki, H., Kurosawa, M., De Strooper, B., Saftig, P., and Nukina, N. (2005) J. Biol. Chem. 280, 23009-23017[Abstract/Free Full Text]
  48. Anderson, J. J., Holtz, G., Baskin, P. P., Turner, M., Rowe, B., Wang, B., Kounnas, M. Z., Lamb, B. T., Barten, D., Felsenstein, K., McDonald, I., Srinivasan, K., Munoz, B., and Wagner, S. L. (2005) Biochem. Pharmacol. 69, 689-698[CrossRef][Medline] [Order article via Infotrieve]
  49. Durkin, J. T., Murthy, S., Husten, E. J., Trusko, S. P., Savage, M. J., Rotella, D. P., Greenberg, B. D., and Siman, R. (1999) J. Biol. Chem. 274, 20499-20504[Abstract/Free Full Text]
  50. Hussain, I., Powell, D., Howlett, D. R., Tew, D. G., Meek, T. D., Chapman, C., Gloger, I. S., Murphy, K. E., Southan, C. D., Ryan, D. M., Smith, T. S., Simmons, D. L., Walsh, F. S., Dingwall, C., and Christie, G. (1999) Mol. Cell. Neurosci. 14, 419-427[CrossRef][Medline] [Order article via Infotrieve]
  51. Sisodia, S., Koo, E., Beyreuther, K., Unterbeck, A., and Price, D. (1990) Science 248, 492-494[Abstract/Free Full Text]
  52. Sisodia, S., Koo, E., Hoffman, P., Perry, G., and Price, D. (1993) J. Neurosci. 13, 3136-3142[Abstract]
  53. Weidemann, A., Konig, G., Bunke, D., Fischer, P., Salbaum, J., Masters, C., and Beyreuther, K. (1989) Cell 57, 115-126[CrossRef][Medline] [Order article via Infotrieve]
  54. Koo, E., Sisodia, S., Archer, D., Martin, L., Weidemann, A., Beyreuther, K., Fischer, P., Masters, C., and Price, D. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 1561-1565[Abstract/Free Full Text]
  55. Kim, K., Miller, D., and Sapienza, V. (1988) Neurosci. Res. Commun. 2, 121-130
  56. Kim, K., Wen, G., and Bancher, C. (1990) Neurosci. Res. Commun. 7, 113-122
  57. Jung, S. S., Gauthier, S., and Cashman, N. R. (1999) Neurobiol. Aging 20, 249-257[CrossRef][Medline] [Order article via Infotrieve]
  58. Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schlossmacher, M., Whaley, J., Swindlehurst, C., McCormack, R., Wolfert, R., Selkoe, D., Lieberburg, I., and Schenk, D. (1992) Nature 359, 325-327